N/A
Manufactured by Amneal Pharmaceuticals LLC
9,857 FDA adverse event reports analyzed
Last updated: 2026-04-15
ALBENDAZOLE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Amneal Pharmaceuticals LLC. The most commonly reported adverse reactions for ALBENDAZOLE include DRUG INEFFECTIVE, OFF LABEL USE, PYREXIA, PRODUCT USE IN UNAPPROVED INDICATION, HEADACHE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ALBENDAZOLE.
Out of 1,828 classified reports for ALBENDAZOLE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 9,857 FDA FAERS reports that mention ALBENDAZOLE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, OFF LABEL USE, PYREXIA, PRODUCT USE IN UNAPPROVED INDICATION, HEADACHE, CONDITION AGGRAVATED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Amneal Pharmaceuticals LLC in connection with ALBENDAZOLE. Always verify the specific product and NDC with your pharmacist.